Diabetic cardiomyopathy--a distinct disease?
Diabetic individuals have a significantly increased likelihood of developing cardiovascular disease. Whilst part of this association is explained by the presence of concomitant risk factors, large epidemiological studies have consistently reported diabetes as a strong risk factor for the development of heart failure after adjusting for such covariates. This has resulted in the notion that there is a distinct cardiomyopathy specific to diabetes, termed 'diabetic cardiomyopathy'. The natural history is characterized by a latent subclinical period, during which there is evidence of diastolic dysfunction and left ventricular hypertrophy, before overt clinical deterioration and systolic failure ensue. These clinical findings have been supported by a growing body of experimental data which support the notion that diabetes inflicts a direct insult to the myocardium, with cellular, structural and functional changes manifest as the diabetic myocardial phenotype. Several of these mechanisms appear to work in unison, forming complicated reciprocal pathways of disease. Reactive oxygen species and alterations in intracellular calcium homeostasis appear to play significant roles in many of these mechanisms. Determining the hierarchy of this cascade of disease will allow identification of the pathological trigger most responsible for disease. Translational research in this field is currently hindered by a lack of clinical studies and intervention trials specifically in patients with diabetic cardiomyopathy. Future clinical and experimental studies of accurate models of diabetic cardiomyopathy should help to define the true aetiology and lead to the development of specific pharmacotherapies for this condition, ultimately reducing the increased cardiovascular morbidity and mortality in diabetic patients.
Khavandi
Kaivan
K
Division of Cardiovascular and Endocrine Sciences, Core Technology Facility, University of Manchester, Manchester, UK.
Khavandi
Ali
A
Asghar
Omar
O
Greenstein
Adam
A
Withers
Sarah
S
Heagerty
Anthony M
AM
Malik
Rayaz A
RA
D000818:Animals; D002118:Calcium / Q000378:metabolism; D009202:Cardiomyopathies / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D048909:Diabetes Complications / Q000175:diagnosis / Q000503:physiopathology*; D005260:Female; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000502:physiology; D008279:Magnetic Resonance Imaging; D008297:Male; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000009:adverse effects; D012084:Renin-Angiotensin System / Q000502:physiology; D018487:Ventricular Dysfunction, Left / Q000209:etiology
D051793:Hypoxia-Inducible Factor 1; D017382:Reactive Oxygen Species; D011065:Poly(ADP-ribose) Polymerases; D011493:Protein Kinase C; D002118:Calcium